ABSTRACT
Introduction .................................................................................................................................... 559 31.1 Prevalence of Sexual Dysfunctions .................................................................................... 559 31.2 d-Aspartic Acid................................................................................................................... 559
31.2.1 Background ...........................................................................................................560 31.2.2 Clinical Research ..................................................................................................560 31.2.3 Adverse Reactions/Drug Interactions ...................................................................560 31.2.4 Comments .............................................................................................................560
